Characterization of biocompatible polyelectrolyte complex multilayer of hyaluronic acid and poly-l-lysine
A biocompatible polyelectrolyte complex multilayer (PECML) film consisting of poly-L-lysine (PLL) as a polycation and hyaluronic acid (HA) as a polyanion was developed to test its use for surface modification to prevent cell attachment and protein drug delivery. The formation of PECML through the electrostatic interaction of HA and PLL was confirmed by contact angle measurement, ESCA analysis, and HA content analysis. HA content increased rapidly up to 8 cycles for HA/PLL deposition and then slightly increased with an increasing number of deposition cycle.In vitro release of PLL in the PECML continued up to 4 days andca. 25% of HA remained on the chitosan-coated cover glass afterin vitro release test for 7 days. From the results, PECML of HA and PLL appeared to be stable for about 4 days. The surface modification of the chitosan-coated cover glass with PECML resulted in drastically reduced peripheral blood mononuclear cell (PBMC) attachment. Concerned with its use for protein drug delivery, we confirmed that bovine serum albumin (BSA) as a model protein could be incorporated into the PECML and its release might be triggered by the degradation of HA with hyaluronidase.
Keywordspolyelectrolyte complex multilayer hyaluronic acid poly-L-lysine surface modification peripheral blood mononuclear cell
Unable to display preview. Download preview PDF.
- Gao, M., B. Richter, S. Kirstein, and H. Mhwald (1998) Electroluminescence studies on self-assembled films of PPV and CdSe nanoparticles.J. PhysChem. 102: 4096–4103.Google Scholar
- Laurent, T. C. (1998)The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives. Wenner-Gren International Series, Vol. 72. Portland Press, London, UK.Google Scholar
- Balazs, E. A. and J. L. Denlinger (1993) Viscosupplementation: A new concept in the treatment of osteoarthritis.J. Rheumatol. 20: 3–9.Google Scholar
- Balazs, E. A. (1983) Sodium hyaluronate and viscosurgery. pp. 5–28. In: Miller D. and Stegmann R. (eds.).Healon (Sodium Hyaluronate). A Guide to Its Use in Ophthalmic Surgery. Wiley, New York, USA.Google Scholar
- Vercruysse K. P. and G. D. Prestwich (1998) Hyaluronate derivatives in drug delivery.Crit. Rev. Therap. Carr. Sys. 15: 513–555.Google Scholar
- Balazs, E. A. and A. Leshchiner (1986) Cross-linked gels of hyaluronic acid and products containing such gels.US Patent 4,582,865.Google Scholar
- Balazs, E. A. and A. Leshchiner (1987) Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues.US Patent 4,713,448.Google Scholar
- Hahn, S. and T. Shimobouji (2003) Sustained release formulation of protein drugs.Japanese Patent 2003-385054.Google Scholar
- Hahn, S., T. Shimobouji, and T. Nakamura (2002) Controlled release of protein drugs.Japanese Patent 2002-338167.Google Scholar
- Shu, X. Z., Y. Liu, F. Palumbo, Y. Luo, and G. D. Prestwich (2003)In situ crosslinkable hyaluronan hydrogels for tissue engineering.Biomaterials 25: 1339–1348.Google Scholar
- Hahn, S., S. Jelacic, R. V. Maier, P. S. Stayton, and A. S. Hoffman (2004) Anti-inflammatory drug release from hyaluronic acid hydrogels.J. Biomat. Sci. Polym. Ed. In press.Google Scholar